Panel Intelligence, LLC, April 2008
Covered: Oncology
Region: United States Only
Methodology: Online survey, self-administered via a Panel Intelligence website
Duration: 30 minutes
Size: 50 total respondents
Fielding Dates: April 10-15
Panel Intelligence, LLC, Dec 2007
Intelligence website
- Duration: 30 minutes
- Size: 51 respondents
- Fielding dates: November 28 to December 2, 2007
Objectives: To periodically track changes in usage of Revlimid by surveying a set of
Panel Intelligence, LLC, June 2007, Minutes: 20
professional time in clinical practice
- Manages at least 200 oncology patients on average per month
- Currently uses ESAs to treat oncology patients
Arrowhead Publishers, Aug 2008, Pages: 318
Table 3.19 Key Patent Expirations in the US Cancer Market
Table 4.1 The Stages of Colorectal Cancer
Table 4.2 Principal Therapies for Colorectal Cancer 2008
Table 4.3 Patent Approval and Expiry dates
Panel Intelligence, LLC, Feb 2008
.
Inclusion Criteria
- Board-certified in Medical Oncology or Hematology/Oncology
- In practice between 2 and 30 years
- Spends at least 50% of professional time in clinical practice
- Seen at least 10
Decision Resources, Inc., March 2009, Pages: 49
Oncology Deals, 2008
- Biosimilar Agents in the European Union and the United States
- Generic Expansion into Japan, Q4 2008
List of Figures
- Qualitative Assessment of Implications of US Healthcare
Arrowhead Publishers, Nov 2009
-cell lung cancer (SCLC) patients unsuitable for surgical resection, drug therapy plays a vital role in the management of lung cancer. Such high level of unmet need ensures the lung cancer market is an
Datamonitor, July 2010, Pages: 114
Opportunity 1: aging population will result in increasing cancer incidence
Opportunity 2: oncology therapy sales continue to experience strong growth
Opportunity 3: high levels of unmet need
Threat 1
Datamonitor, July 2010, Pages: 111
competition in the oncology market
Threat 2: the cost of drug development continues to rise
Threat 3: ongoing cost-containment measures
US
Current and future market assessment
The US antihormonals market
Decision Resources, Inc., June 2009, Pages: 47
Biopharma Quarter: Key Trends and Events of the First Quarter of 2009 No Bear Stearns, no Lehman Brothers, no Chrysler, no humiliating hat-in-hand audiences with Congress. The biopharma industry has
Datamonitor, Aug 2010, Pages: 132
profiles and analysis for the key brands, including approval dates, patent expiries and all key events likely to impact sales
-Snapshot of the cancer targeted therapies and immunotherapies market in the
Decision Resources, Inc., Dec 2007, Pages: 40
, Pfizer, and Neurochem.
- Upcoming patent effects on current blockbusters: patent expiry datesin each of the seven major markets for 2006’s best-selling prescription drugs in the world; the late-stage
Espicom Business Intelligence Ltd, Feb 2012, Pages: 306
Tovok This report has been written by Sue Viney, a senior writer on Espicom’s oncology analysis team. Sue has been evaluating companies, products and drugs in research for 12 years. She is editor of
Datamonitor, Oct 2008, Pages: 144
post-mega merger era 24
Drivers and resistors of M&As 26
Drivers of M&A in Pharma 26
The number of new drugs entering clinical trials has been declining 26
Looming patent expiration dates and growing
CYGNUS Business Consulting & Research, July 2009, Pages: 205
, profitability, balance sheet analysis sand key financial ratios.
The Indian healthcare system dates back to the Vedic system of healthcare (Ayurveda) in 5000 BC. The Ayurvedic principles of positive health and
Espicom Business Intelligence Ltd, Nov 2010, Pages: 228
and oncology.
Employing over 116,500 people worldwide, it has more than 100 overseas subsidiaries and operations in around 150 countries.
Pfizer believes it has one of the broadest product portfolios
Markets and Markets, April 2012, Pages: 271
out to be a potential transformative diagnostic tool especially for the oncology studies. This shift from the academics to the clinical and diagnostics lab is mainly due to speedy improvements in the
Global Markets Direct, Jan 2009, Pages: 19
investigational products. The report also provides details on clinical trials covering trial phase, description, investigator information, primary and secondary end-points and trial results for products in
